Follow-up:

FDA approved tirzepatide to treat Cellosis (new clari-
fying name for type 2 diabetes) May 13 2022. In April
2023, Lilly may submit it to FDA to be approved as a
weight loss drug, but I'm not sure who will & who won't
qualify to use the drug for that purpose. Also, current
information indicates many insurers won't cover the
drug for weight loss.

- - -
March 3 2023

Tirzepatide: ... a new era of weight loss — because
this one works. Scientists are still figuring out why
tirzepatide causes weight loss. One theory is that
they “accidentally” created a new hormone. https://bigthink.com/health/tirzepatide-novel-obesity-drug-actually-works/
- - -

... Semaglutide, approved in 2021, helped 86% of
patients drop at least 5% of their body weight, with
an average weight loss of 15% (compared to 2.4%
for placebo). Since its approval, semaglutide (sold
under the brand name Wegovy) has been hailed as
a “transformative breakthrough” in the battle against
[stoutness].

However, the new drug, tirzepatide, has left semag-
lutide in its shadow: 91% of patients saw a reduction
of at least 5%, with an average weight loss of 21% for
the highest dose (compared to 3.1% for placebo).

... Eli Lilly, tirzepatide’s manufacturer, doesn’t need
to understand why exactly the drug works in order
to bring it to market. The company plans to apply
for drug approval (as a weight loss drug?) in April
2023.

Tirzepatide was approved to treat Cellosis (see
description of Cellosis in post below for details
on what Cellosis is) on May 13 2022: https://www.google.com/search?q=tirzepatide+fda+approval

https://www.google.com/search?q=Tirzepatide

All of the tirzepatide articles that use diabetes
without clarifier, fact is they're all solely referring
to Cellosis (see previous post below for details).

As for BMI 30 & above, see the following graphic
for new preferred clarifying words to put an end
to the pejorative nature of most weight words:

BMI, Waist Circumference, & Associated Disease Risks https://prohuman.net/pix2/BMI-WaistCircumference-Cellosis&Hypertension&CardiovascularDisease-Risk.jpg

As for what weight the use of tirzepatide would
be approved for, I don't know. As for whether or
not it might be approved for Ample weight indi-
viduals (BMI 25 to 29.9), as a preventative for
further weight gain, I don't know.

As for whether or not it might be approved for
Average weight individuals (BMI 18.5 to 24.9)
who simply want to be thinner, I doubt it but I
don't know.

As for how high the risk is for possible thyroid
tumors, I don't know.

Its current approval says it's not for use to treat
Islit (Insulinitis - see description in previous post
below) but I don't know if those with Islit might
be able to use tirzepatide to lose weight or if the
use of tirzepatide would increase the hypogly-
cemia risk for those with Islit & for those with ...

... any other Disparate High Glucose Condition
who are using any medications that cause hypo-
glycemia.

Side effects & other medication information: https://uspl.lilly.com/mounjaro/mounjaro.html#mg

On Wednesday, March 3, 2021 at 9:14:09 AM UTC-6, _ wrote:

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Cellosis, superior new clarifying name
for continued insulin production unable to
keep glucose level < HbA1c 6.5, modest
risk usually at weight with BMI 25-29.9, a
greater risk with weight BMI = or > 30, ...

... greatest risk with weight BMI 35 or higher
with the highest risk with BMI in the stratos-
phere; however, old age increases risk apart
from weight issues, and high carb diets as
well as sparse exercise increases risk even ...

... at BMI < 25. Inherited polygenetic risk
(from one or both parents having Cellosis)
also can play a causal factor.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

o Phase 3 clinical trials comparing the use of
Tirzepatide injections in Cellosis individuals
who use either Degludec or Glargine insulin
injections with or without Metformin

o Tirzepatide injections reduced HbA1c by an
average of 2.5 percentage points and led to a
weight loss of 24-28 pounds

o Tirzepatide injections reduced high incidence
of hypoglycemia dramatically

o Unknown when or if Tirzepatide injections may
be approved to treat Cellosis and/or BMI 30 and
above

February 17 2021 https://diatribe.org/breaking-news-tirzepatide-most-buzzworthy-drug-development

February 17 2021 https://finance.yahoo.com/news/tirzepatide-significantly-reduced-a1c-body-114500358.html

February 22 2021
Tirzepatide and the Search for Better
BMI 30 and Above Treatment https://conscienhealth.org/2021/02/tirzepatide-and-the-search-for-better-obesity-treatment/

March 3 2021 https://diabetestimes.co.uk/tirzepatide-reduces-hba1c-levels-and-body-weight-in-people-with-type-2-diabetes/

*** *** *** *** *** *** *** *** *** *** *** ***

- - -
diabetes / diabetic without a clarifier,
diabetes / diabetic guessing required https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
- - -

Pro-Humanist FREELOVER, Insulitis Islit
(Islit, the abbreviation for Insulinitis) since
age 5, March 1961, promoting replacement
of all of the outdated ancient confusing mis-
leading diabetes / diabetic words & phrases
& the confusing reactive hypoglycemia ...

... phrase with new superior clarifying noncon-
fusing nonmisleading words & phrases & def-
initions which were initially first proposed in
May, 2010:

Diabetes Bubble / Diabetes Bubble Burst
(outstanding) https://prohuman.net/diabetesbubblediabetesbubbleburst.htm

C.ure I.nsulinitis A.ssociation
(hopefully) https://prohuman.net/cureinsulinitisassociation.htm

Glucose Anomalies Research regarding
Potential Cures / Improvements in Treatments
(hopefully) https://prohuman.net/glucoseanomaliesresearch.htm

Insulinitis (Islit) is the near-total to total
loss of endogenous insulin, requires
multiple daily dosages of basal & bolus
insulin to try to stay alive, every dosage
a high risk in that severe hypoglycemia
kills an estimated 5% to 11% Islit indivi-
duals.

There are 13 specific types of Insulinitis
(Islit) that are rapid-onset, and 1 specific
type (Latent Autoimmune Islit) that is slow
onset. https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg

- - -

As for the most widespread High Glucose
Conditions, 20 specific types of Cellosis
(new clarifying name for type 2 diabetes)
are unpreventable & nonreversible (thus
far).

The only specific type of ANY of the over
80 disparate specific types of High Glu-
cose Conditions that is preventable (in
many, with lifestyle changes) & reversible
(possible if action is taken up to 10 years
after diagnosis), Preventable Cellosis.

Due to the slow onset of Cellosis, typic-
ally, the prestage with good chance of
Cellosis prevention = PreCellosis (the
old confusing name is prediabetes), the
HbA1c slightly above normal (5.7 to 6.4
in those with no High Glucose Condition).

*** *** *** *** *** *** *** *** *** *** *** ***

--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)

(re-post to improve clarity & accurately
depict who was involved in the study)

Follow-up 2:

- - -
May 19 2023

Tirzepatide improves body composition
across a range of adult age groups,
study shows https://www.news-medical.net/news/20230519/Tirzepatide-improves-body-composition-across-a-range-of-adult-age-groups-study-shows.aspx
- - -

A new analysis of SURMOUNT-1, the first
Phase 3 study of tirzepatide in adults for
chronic weight management shows that
tirzepatide improves body composition
across a range of adult age groups.

... The efficacy and safety of tirzepatide,
a glucose-dependent insulinotropic poly-
peptide (GIP) and glucagon-like peptide-1
(GLP-1) receptor agonist, in people with
[BMI 27 or higher] was investigated in
SURMOUNT-1, the complete trial for ...

... which was published in NEJM in July
2022.

GIP and GLP-1 are hormones that are
involved in blood sugar control & body
weight regulation. After a person has
eaten, these hormones are secreted by
cells of the intestines and in turn cause
the secretion of insulin [in persons ...

... with a fully function pancreas]. Tirzep-
atide activates both the GLP-1 & GIP re-
ceptors, leading to improved blood sugar
control & enhanced satiety.

Tirzepatide is approved in the USA & the
European Union to treat Cellosis [old out-
dated name type 2 diabetes], but is not
yet approved for [BMI 30 & higher or per
the study, BMI 27 & higher] treatment in
any country.

The manufacturer of tirzepatide, Eli Lilly
& Company, intends to seek approval for
the drug as a [BMI 30 & higher or, per the
study, BMI 27 & higher] treatment from the
US Food and Drug Administration (FDA),
the European Union, & other territories
beginning in 2023.

[see article for details on individuals
without any of the 7 Disparate High Glu-
cose Conditions (DHGCs) who had a
BMI of 27 or higher that were involved
in the study]

On Saturday, March 4, 2023 at 9:33:27 AM UTC-6, _ wrote:

Follow-up:

FDA approved tirzepatide to treat Cellosis (new clari-
fying name for type 2 diabetes) May 13 2022. In April
2023, Lilly may submit it to FDA to be approved as a
weight loss drug, but I'm not sure who will & who won't
qualify to use the drug for that purpose. Also, current
information indicates many insurers won't cover the
drug for weight loss.

- - -
March 3 2023

Tirzepatide: ... a new era of weight loss — because
this one works. Scientists are still figuring out why
tirzepatide causes weight loss. One theory is that
they “accidentally” created a new hormone. https://bigthink.com/health/tirzepatide-novel-obesity-drug-actually-works/
- - -

... Semaglutide, approved in 2021, helped 86% of
patients drop at least 5% of their body weight, with
an average weight loss of 15% (compared to 2.4%
for placebo). Since its approval, semaglutide (sold
under the brand name Wegovy) has been hailed as
a “transformative breakthrough” in the battle against
[stoutness].

However, the new drug, tirzepatide, has left semag-
lutide in its shadow: 91% of patients saw a reduction
of at least 5%, with an average weight loss of 21% for
the highest dose (compared to 3.1% for placebo).

... Eli Lilly, tirzepatide’s manufacturer, doesn’t need
to understand why exactly the drug works in order
to bring it to market. The company plans to apply
for drug approval (as a weight loss drug?) in April
2023.

Tirzepatide was approved to treat Cellosis (see
description of Cellosis in post below for details
on what Cellosis is) on May 13 2022: https://www.google.com/search?q=tirzepatide+fda+approval

https://www.google.com/search?q=Tirzepatide

All of the tirzepatide articles that use diabetes
without clarifier, fact is they're all solely referring
to Cellosis (see previous post below for details).

As for BMI 30 & above, see the following graphic
for new preferred clarifying words to put an end
to the pejorative nature of most weight words:

BMI, Waist Circumference, & Associated Disease Risks https://prohuman.net/pix2/BMI-WaistCircumference-Cellosis&Hypertension&CardiovascularDisease-.Risk.jpg

As for what weight the use of tirzepatide would
be approved for, I don't know. As for whether or
not it might be approved for Ample weight indi-
viduals (BMI 25 to 29.9), as a preventative for
further weight gain, I don't know.

As for whether or not it might be approved for
Average weight individuals (BMI 18.5 to 24.9)
who simply want to be thinner, I doubt it but I
don't know.

As for how high the risk is for possible thyroid
tumors, I don't know.

Its current approval says it's not for use to treat
Islit (Insulinitis - see description in previous post
below) but I don't know if those with Islit might
be able to use tirzepatide to lose weight or if the
use of tirzepatide would increase the hypogly-
cemia risk for those with Islit & for those with ...

... any other Disparate High Glucose Condition
who are using any medications that cause hypo-
glycemia.

Side effects & other medication information: https://uspl.lilly.com/mounjaro/mounjaro.html#mg

On Wednesday, March 3, 2021 at 9:14:09 AM UTC-6, _ wrote:

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Cellosis, superior new clarifying name
for continued insulin production unable to
keep glucose level < HbA1c 6.5, modest
risk usually at weight with BMI 25-29.9, a
greater risk with weight BMI = or > 30, ...

... greatest risk with weight BMI 35 or higher
with the highest risk with BMI in the stratos-
phere; however, old age increases risk apart
from weight issues, and high carb diets as
well as sparse exercise increases risk even ...

... at BMI < 25. Inherited polygenetic risk
(from one or both parents having Cellosis)
also can play a causal factor.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

o Phase 3 clinical trials comparing the use of
Tirzepatide injections in Cellosis individuals
who use either Degludec or Glargine insulin
injections with or without Metformin

o Tirzepatide injections reduced HbA1c by an
average of 2.5 percentage points and led to a
weight loss of 24-28 pounds

o Tirzepatide injections reduced high incidence
of hypoglycemia dramatically

o Unknown when or if Tirzepatide injections may
be approved to treat Cellosis and/or BMI 30 and
above

February 17 2021 https://diatribe.org/breaking-news-tirzepatide-most-buzzworthy-drug-development

February 17 2021 https://finance.yahoo.com/news/tirzepatide-significantly-reduced-a1c-body-114500358.html

February 22 2021
Tirzepatide and the Search for Better
BMI 30 and Above Treatment https://conscienhealth.org/2021/02/tirzepatide-and-the-search-for-better-obesity-treatment/

March 3 2021 https://diabetestimes.co.uk/tirzepatide-reduces-hba1c-levels-and-body-weight-in-people-with-type-2-diabetes/

*** *** *** *** *** *** *** *** *** *** *** ***

- - -
diabetes / diabetic without a clarifier,
diabetes / diabetic guessing required https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
- - -

Pro-Humanist FREELOVER, Insulitis Islit
(Islit, the abbreviation for Insulinitis) since
age 5, March 1961, promoting replacement
of all of the outdated ancient confusing mis-
leading diabetes / diabetic words & phrases
& the confusing reactive hypoglycemia ...

... phrase with new superior clarifying noncon-
fusing nonmisleading words & phrases & def-
initions which were initially first proposed in
May, 2010:

Diabetes Bubble / Diabetes Bubble Burst
(outstanding) https://prohuman.net/diabetesbubblediabetesbubbleburst.htm

C.ure I.nsulinitis A.ssociation
(hopefully) https://prohuman.net/cureinsulinitisassociation.htm

Glucose Anomalies Research regarding
Potential Cures / Improvements in Treatments
(hopefully) https://prohuman.net/glucoseanomaliesresearch.htm

Insulinitis (Islit) is the near-total to total
loss of endogenous insulin, requires
multiple daily dosages of basal & bolus
insulin to try to stay alive, every dosage
a high risk in that severe hypoglycemia
kills an estimated 5% to 11% Islit indivi-
duals.

There are 15 specific types of Insulinitis
(Islit) that are rapid-onset, and 1 specific
type (Latent Autoimmune Islit) that is slow
onset. https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg

- - -

As for the most widespread High Glucose
Conditions, 20 specific types of Cellosis
(new clarifying name for type 2 diabetes)
are unpreventable & nonreversible (thus
far).

The only specific type of ANY of the over
80 disparate specific types of High Glu-
cose Conditions that is preventable (in
many, with lifestyle changes) & reversible
(possible if action is taken up to 10 years
after diagnosis), Preventable Cellosis.

Due to the slow onset of Cellosis, typic-
ally, the prestage with good chance of
Cellosis prevention = PreCellosis (the
old confusing name is prediabetes), the
HbA1c slightly above normal (5.7 to 6.4
in those with no High Glucose Condition).

*** *** *** *** *** *** *** *** *** *** *** ***

--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)

Follow-up 2:

- - -
May 19 2023

Tirzepatide improves body composition
across a range of adult age groups,
study shows https://www.news-medical.net/news/20230519/Tirzepatide-improves-body-composition-across-a-range-of-adult-age-groups-study-shows.aspx
- - -

A new analysis of SURMOUNT-1, the first
Phase 3 study of tirzepatide in adults for
chronic weight management shows that
tirzepatide improves body composition
across a range of adult age groups.

... The efficacy and safety of tirzepatide,
a glucose-dependent insulinotropic poly-
peptide (GIP) and glucagon-like peptide-1
(GLP-1) receptor agonist, in people with
[BMI 30 or higher] obesity was investi-
gated in SURMOUNT-1, the complete ...

... trial for which was published in NEJM
in July 2022.

GIP and GLP-1 are hormones that are
involved in blood sugar control & body
weight regulation. After a person has
eaten, these hormones are secreted by
cells of the intestines and in turn cause
the secretion of insulin [in persons ...

... with a fully function pancreases]. Tir-
zepatide activates both the GLP-1 & GIP
receptors, leading to improved blood
sugar control & enhanced satiety.

Tirzepatide is approved in the USA & the
European Union to treat Cellosis [old out-
dated name type 2 diabetes], but is not
yet approved for [BMI 30 & higher] treat-
ment in any country.

The manufacturer of tirzepatide, Eli Lilly
& Company, intends to seek approval for
the drug as a [BMI 30 & higher] treatment
from the US Food and Drug Administra-
tion (FDA), the European Union, & other
territories beginning in 2023.

[see article for details on individuals
without any of the 7 Disparate High Glu-
cose Conditions (DHGCs) who had a
BMI of 27 or higher that were involved
in the study]

On Saturday, March 4, 2023 at 9:33:27 AM UTC-6, _ wrote:

Follow-up:

FDA approved tirzepatide to treat Cellosis (new clari-
fying name for type 2 diabetes) May 13 2022. In April
2023, Lilly may submit it to FDA to be approved as a
weight loss drug, but I'm not sure who will & who won't
qualify to use the drug for that purpose. Also, current
information indicates many insurers won't cover the
drug for weight loss.

- - -
March 3 2023

Tirzepatide: ... a new era of weight loss — because
this one works. Scientists are still figuring out why
tirzepatide causes weight loss. One theory is that
they “accidentally” created a new hormone. https://bigthink.com/health/tirzepatide-novel-obesity-drug-actually-works/ - - -

... Semaglutide, approved in 2021, helped 86% of
patients drop at least 5% of their body weight, with
an average weight loss of 15% (compared to 2.4%
for placebo). Since its approval, semaglutide (sold
under the brand name Wegovy) has been hailed as
a “transformative breakthrough” in the battle against
[stoutness].

However, the new drug, tirzepatide, has left semag-
lutide in its shadow: 91% of patients saw a reduction
of at least 5%, with an average weight loss of 21% for
the highest dose (compared to 3.1% for placebo).

... Eli Lilly, tirzepatide’s manufacturer, doesn’t need
to understand why exactly the drug works in order
to bring it to market. The company plans to apply
for drug approval (as a weight loss drug?) in April
2023.

Tirzepatide was approved to treat Cellosis (see
description of Cellosis in post below for details
on what Cellosis is) on May 13 2022: https://www.google.com/search?q=tirzepatide+fda+approval

https://www.google.com/search?q=Tirzepatide

All of the tirzepatide articles that use diabetes
without clarifier, fact is they're all solely referring
to Cellosis (see previous post below for details).

As for BMI 30 & above, see the following graphic
for new preferred clarifying words to put an end
to the pejorative nature of most weight words:

BMI, Waist Circumference, & Associated Disease Risks https://prohuman.net/pix2/BMI-WaistCircumference-Cellosis&Hypertension&CardiovascularDisease-.Risk.jpg

As for what weight the use of tirzepatide would
be approved for, I don't know. As for whether or
not it might be approved for Ample weight indi-
viduals (BMI 25 to 29.9), as a preventative for
further weight gain, I don't know.

As for whether or not it might be approved for
Average weight individuals (BMI 18.5 to 24.9)
who simply want to be thinner, I doubt it but I
don't know.

As for how high the risk is for possible thyroid
tumors, I don't know.

Its current approval says it's not for use to treat
Islit (Insulinitis - see description in previous post
below) but I don't know if those with Islit might
be able to use tirzepatide to lose weight or if the
use of tirzepatide would increase the hypogly-
cemia risk for those with Islit & for those with ...

... any other Disparate High Glucose Condition
who are using any medications that cause hypo-
glycemia.

Side effects & other medication information: https://uspl.lilly.com/mounjaro/mounjaro.html#mg

On Wednesday, March 3, 2021 at 9:14:09 AM UTC-6, _ wrote:

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Cellosis, superior new clarifying name
for continued insulin production unable to
keep glucose level < HbA1c 6.5, modest
risk usually at weight with BMI 25-29.9, a
greater risk with weight BMI = or > 30, ...

... greatest risk with weight BMI 35 or higher
with the highest risk with BMI in the stratos-
phere; however, old age increases risk apart
from weight issues, and high carb diets as
well as sparse exercise increases risk even ...

... at BMI < 25. Inherited polygenetic risk
(from one or both parents having Cellosis)
also can play a causal factor.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

o Phase 3 clinical trials comparing the use of
Tirzepatide injections in Cellosis individuals
who use either Degludec or Glargine insulin
injections with or without Metformin

o Tirzepatide injections reduced HbA1c by an
average of 2.5 percentage points and led to a
weight loss of 24-28 pounds

o Tirzepatide injections reduced high incidence
of hypoglycemia dramatically

o Unknown when or if Tirzepatide injections may
be approved to treat Cellosis and/or BMI 30 and
above

February 17 2021 https://diatribe.org/breaking-news-tirzepatide-most-buzzworthy-drug-development

February 17 2021 https://finance.yahoo.com/news/tirzepatide-significantly-reduced-a1c-body-114500358.html

February 22 2021
Tirzepatide and the Search for Better
BMI 30 and Above Treatment https://conscienhealth.org/2021/02/tirzepatide-and-the-search-for-better-obesity-treatment/

March 3 2021 https://diabetestimes.co.uk/tirzepatide-reduces-hba1c-levels-and-body-weight-in-people-with-type-2-diabetes/

*** *** *** *** *** *** *** *** *** *** *** ***

- - -
diabetes / diabetic without a clarifier,
diabetes / diabetic guessing required https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
- - -

Pro-Humanist FREELOVER, Insulitis Islit
(Islit, the abbreviation for Insulinitis) since
age 5, March 1961, promoting replacement
of all of the outdated ancient confusing mis-
leading diabetes / diabetic words & phrases
& the confusing reactive hypoglycemia ...

... phrase with new superior clarifying noncon-
fusing nonmisleading words & phrases & def-
initions which were initially first proposed in
May, 2010:

Diabetes Bubble / Diabetes Bubble Burst
(outstanding) https://prohuman.net/diabetesbubblediabetesbubbleburst.htm

C.ure I.nsulinitis A.ssociation
(hopefully) https://prohuman.net/cureinsulinitisassociation.htm

Glucose Anomalies Research regarding
Potential Cures / Improvements in Treatments
(hopefully) https://prohuman.net/glucoseanomaliesresearch.htm

Insulinitis (Islit) is the near-total to total
loss of endogenous insulin, requires
multiple daily dosages of basal & bolus
insulin to try to stay alive, every dosage
a high risk in that severe hypoglycemia
kills an estimated 5% to 11% Islit indivi-
duals.

There are 15 specific types of Insulinitis
(Islit) that are rapid-onset, and 1 specific
type (Latent Autoimmune Islit) that is slow
onset. https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg

- - -

As for the most widespread High Glucose
Conditions, 20 specific types of Cellosis
(new clarifying name for type 2 diabetes)
are unpreventable & nonreversible (thus
far).

The only specific type of ANY of the over
80 disparate specific types of High Glu-
cose Conditions that is preventable (in
many, with lifestyle changes) & reversible
(possible if action is taken up to 10 years
after diagnosis), Preventable Cellosis.

Due to the slow onset of Cellosis, typic-
ally, the prestage with good chance of
Cellosis prevention = PreCellosis (the
old confusing name is prediabetes), the
HbA1c slightly above normal (5.7 to 6.4
in those with no High Glucose Condition).

*** *** *** *** *** *** *** *** *** *** *** ***

--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)